Vor Biopharma Inc.

New York University

Modernatx, Inc.

Puretech Health, LLC

Puretech Lyt, Inc.

Joseph Beene Bolen

Aleksandar Filip Radovic-Moreno

Noubar Boghos Afeyan

Stephen G Hoge

John Lydeard

George Miller

Eric Elenko

Shohei Koide

Akiko Koide

Joshua P Frederick

Jeff Lynn Ellsworth

Justin Guild

Eric Yi-Chun Huang

Antonin De Fougerolles

Aleksandra Filipovic

Linxiao Chen

Örn Almarsson

Staci Sabnis

Francine M Gregoire

Tatyana Panchenko

Takamitsu Hattori

Sushma Gurumurthy

Kristine McKinney

Christina Henderson

Stephen Michael Kelsey

Kahlin Cheung-ong

Josh Frederick

Michael Morin

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

Genetically engineered hematopoietic stem cells and uses thereof

Disclosed herein are antibodies specific to a delta-1 chain of a γδ T cell receptor and methods of using such for modulating γδ T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with γδ T cell activation, such as solid tumors, or for detecting presence of γδ1 T cells.

Antibodies specific to delta 1 chain of T cell receptor

Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.

Compositions and methods for inhibition of lineage specific proteins

Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Anti-galectin-9 antibodies and uses thereof

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.

Polynucleotides encoding immune modulating polypeptides

Anti-Galectin-9 antibodies and uses thereof

Growing community of inventors

Cambridge, MA, United States of America

Joseph Beene Bolen